ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  


ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Rigurosity RigurosityOur clinical studies are rigurously analyzed Efficiency EfficiencyWe optimize our own resources Agility AgilityWe adopt agile decissions


Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.


ADmit Therapeutics announces a new investment of up to $1,886,058 from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation.
The investment represents a continuation of the Diagnostics Accelerator’s support for the clinical validation and regulatory approval of our breakthrough technology based on novel biomarkers related to mitochondrial DNA. Mitochondrial DNA is the circular chromosome found inside mitochondria, which are responsible for ...

read more


Marta Barrachina Marta BarrachinaCEO
Ramón Reñé Ramón ReñéMedical Advisory Board

Jordi Gascón Jordi GascónMedical Advisory Board

Horizon 2020 EIT Health
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I Agree  How to configure browser